Atoguanil - Ipca Laboratories/Medicines for Malaria Venture
Alternative Names: Atovaquone/proguanil - Ipca Laboratories/Medicines for Malaria VentureLatest Information Update: 02 Jan 2024
At a glance
- Originator Ipca Laboratories; Medicines for Malaria Venture
- Class Antimalarials; Biguanides; Chlorobenzenes; Cyclohexenes; Small molecules
- Mechanism of Action Electron transport complex I inhibitors; Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Malaria
Most Recent Events
- 22 Dec 2023 Discontinued - Clinical-Phase-Unknown for Malaria (Prevention) in India (unspecified route) (MMV pipeline, December 2023)
- 22 Dec 2022 Discontinued - Clinical-Phase-Unknown for Malaria (Prevention) in Switzerland (unspecified route) (MMV pipeline, December 2023)
- 24 Mar 2021 Clinical trials in Malaria (Prevention) in India (unspecified route) before March 2021 (IPCA laboratories website, March 2021)